Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Hon är KI-bolaget Neobiomics nya vd

Neobiomics, som utvecklar produkter inom neonatalområdet, har utsett Emma Höglund till ny vd.

Scientific Solutions

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”

Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Vad är bäst- Android eller Iphone?

När det kommer till att välja telefon finns det ju en uppsjö av telefoner att välja emellan. De två största operativsystemen är helt klart Android och Iphone iO...

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Peter Almgren är ny RWE-statistiker på SDS Life Science

Peter Almgren förstärker företagets Real World Evidence-avdelning och närvaro i Lund.

SDS sätter i gång ny webinarserie

Webinarserie för dig som utvecklar läkemedel eller medicinteknik. Webinarerna kommer att genomföras en gång i månaden och startar den 20 oktober.

Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...

VPN till Android skyddar din data och identitet

För att hålla din Android säker från intrång från hackare så kan du använda VPN, antivirusprogram och säkerhetskopiering. Läs mer här!

No longer afraid of the dentist.

Teaching robot with piezo technology

Study: Chat GPT is more empathetic than doctors

The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic than real doctors, a new study reveals....

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

A world-class research village

Eight years ago, Medicon Village was set up in Lund. Since then, this hub for research, innovation and business has developed enormously, and today the life sci...

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...

SDS-koncernen köps av amerikanskt bolag

Cytel Inc, med huvudkontor i Massachusetts, USA, förvärvar det svenska konsultbolaget SDS Life Science.

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.